首页> 外文期刊>Respiratory Research >Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis
【24h】

Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis

机译:BMPR2突变肺动脉高压患者的性别差异:META分析

获取原文
           

摘要

OBJECTIVE:To investigate the differences in the proportions of BMPR2 mutations in familial hereditary pulmonary arterial hypertension (HPAH) and idiopathic pulmonary arterial hypertension (IPAH) between males and females and the relationship between BMPR2 mutation and PAH severity.METHODS:A computer was used to search the electronic Cochrane Library, PubMed/MEDLINE, and EMBASE databases for clinical trials containing information on the relationship between PAH prognosis and BMPR2 mutations through March 2019. After obtaining the data, a meta-analysis was performed using Review Manager Version 5.3 and Stata.RESULTS:A meta-analysis was performed on 17 clinical trials (2198 total patients: 644 male, 1554 female). The results showed that among patients with HPAH and IPAH, the BMPR2 mutation rate is higher in male than in female patients [male group (224/644, 34.78%), female group (457/1554, 29.41%), OR?=?1.30, 95% CI: 1.06~1.60, P?=?0.01, I 2 ?=?10%]. Furthermore, haemodynamic and functional parameters were more severe in IPAH and HPAH patients with BMPR2 mutations than in those without, and those with BMPR2 mutation were diagnosed at a younger age. The risk of death or transplantation was higher in PAH patients with BMPR2 mutations than in those without (OR?=?2.51, 95% CI: 1.29~3.57, P?=?0.003, I 2 ?=?24%). Furthermore, the difference was significant only in male patients (OR?=?5.58, 95% CI: 2.16~14.39, P?=?0.0004, I 2 ?=?0%) and not in female patients (OR?=?1.41, 95% CI: 0.75~2.67, P?=?0.29, I 2 ?=?0%).CONCLUSION:Among patients with HPAH and IPAH, men are more likely to have BMPR2 mutations, which may predict more severe PAH indications and prognosis.
机译:目的:探讨男性遗传性肺动脉高血压(HPAH)和特发性肺动脉高压(IPAH)与女性的BMPR2突变比例的差异,以及BMPR2突变与PAH严重程度的关系。方法:用来搜索电子Cochrane库,PubMed / Medline和Embase数据库,了解临床试验,包含有关PAH预后和BMPR2突变的关系的临床试验,通过2019年3月。获取数据后,使用Review Manager 5.3和Stata进行Meta分析。结果:在17项临床试验中进行了META分析(2198例患者:644名男性,1554名女性)。结果表明,在HPAH和IPAH患者中,男性的BMPR2突变率高于女性患者[男性组(224/644,34.78%),女性组(457/1554,29.41%),或?=? 1.30,95%CI:1.06〜1.60,p?=?0.01,I 2?=?10%]。此外,IPAH和HPAH患者的血液动力学和功能参数比在没有BMPR2突变的情况下更严重,并且在没有BMPR2突变的情况下诊断出较小的人。 PAH患者的死亡或移植风险高于BMPR2突变而不是在没有(或?=?2.51,95%CI:1.29〜3.57,P?= 0.003,I 2?= 24%)。此外,差异仅在雄性患者(或?= 5.58,95%CI:2.16〜14.39,P?=?0.0004,I 2?=?0%)而不是女性患者(或?=?1.41 ,95%CI:0.75〜2.67,p?=?0.29,I 2?=?0%)。结论:HPAH和IPAH的患者中,男性更有可能具有BMPR2突变,这可能预测更严重的PAH指示和预后。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号